ArriVent BioPharma (AVBP) announced that it intends to offer and sell, subject to market and other conditions, $75M of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities are being offered by ArriVent. ArriVent intends to use the net proceeds from the proposed offering, together with its existing cash resources, to support its activities for firmonertinib and its other pipeline programs and for working capital and other general corporate purposes. Goldman Sachs & Co., Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma initiated with a Buy at Clear Street
- ArriVent Biopharma price target raised to $44 from $39 at Oppenheimer
- ArriVent BioPharma Reports Positive Phase 1b Study Results
- ArriVent BioPharma’s Firmonertinib Shows Promise in NSCLC Treatment with Strong Phase 1b Results and Strategic Phase 3 Plans
- Promising Prospects for ArriVent BioPharma: Buy Rating Affirmed Amidst Positive Clinical Data and Increased Target Price